NEW YORK (GenomeWeb) – Raymond James today upgraded its rating for shares of Quest Diagnostics to Outperform, based on expected growth in professional laboratory services and M&A activity.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.